Alzheimer's disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D. - The Peter Attia Drive Recap
Podcast: The Peter Attia Drive
Published: 2026-01-26
Duration: 2 hr 7 min
Summary
This episode delves into how hormonal transitions, particularly menopause, uniquely affect women's brain health and Alzheimer's disease risk, highlighting the importance of understanding these sex differences in diagnosis and treatment.
What Happened
In this episode, Peter Attia hosts Dr. Lisa Mosconi, a leading neuroscientist specializing in the intersection of women's health and brain health. They discuss the alarming fact that Alzheimer's disease disproportionately affects women, a phenomenon not entirely explained by the fact that women generally live longer than men. Dr. Mosconi emphasizes that Alzheimer's is essentially a midlife disease for women, beginning long before symptoms manifest, and underscores that menopause is a critical brain event that alters brain energy, structure, and immune signaling.
Dr. Mosconi's personal connection to Alzheimer's, stemming from her grandmother's battle with the disease and its impact on her family, drives her passion for this research. She explains how many women experience a preclinical phase of Alzheimer's that can last decades, during which subtle changes occur in the brain long before cognitive decline is detectable. This insight is crucial, as it challenges traditional diagnostic timelines and highlights the need for earlier interventions to mitigate risk. The conversation also touches on the role of hormonal therapy, genetic factors like APOE4, and the complexities surrounding the WHI study, which has contributed to confusion regarding menopausal hormone treatment. Dr. Mosconi's new CARE Initiative aims to cut women's Alzheimer's risk in half by 2050, showcasing her commitment to addressing this urgent public health issue.
Key Insights
- Alzheimer's disease is a midlife issue for women, often starting before symptoms appear.
- Menopause is a significant brain event that affects cognitive health and disease risk.
- The preclinical phase of Alzheimer's can last for decades, emphasizing the need for early detection.
- Genetic risks like APOE4 impact women differently than men, complicating diagnosis and treatment.
Key Questions Answered
Why does Alzheimer's disease affect women more than men?
Dr. Mosconi explains that while women's longer lifespan contributes to higher Alzheimer's rates, it doesn't account for the entire difference. The disease begins earlier for women, particularly in relation to hormonal changes during menopause, which fundamentally alters brain function.
What is the significance of menopause in relation to Alzheimer's?
Menopause is described as a critical brain event by Dr. Mosconi, impacting brain energy, structure, and immune response. These changes can increase the risk of Alzheimer's disease, highlighting the need for focused research on women's health during these transitions.
How does the preclinical phase of Alzheimer's work?
Dr. Mosconi notes that this phase can last decades, where changes in the brain occur before any cognitive impairment is detectable. This emphasizes the importance of early interventions as many individuals may be aware that something is changing, even if they can't identify it.
What role does genetic risk play in Alzheimer's for women?
Genetic factors like APOE4 are discussed as having a more pronounced effect on women than men. Dr. Mosconi indicates that understanding these genetic risks is crucial in tailoring prevention and treatment strategies for women.
What is the CARE Initiative?
The CARE Initiative, led by Dr. Mosconi, is a global effort aimed at reducing women's Alzheimer's risk by half by 2050. This initiative focuses on raising awareness and developing strategies to address the unique challenges women face regarding Alzheimer's disease.